|
FY2025
12 months to Dec 31, 2025
|
FY2024
6 months to Dec 31, 2024
|
FY2023
12 months to Jun 30, 2024
|
FY2022
12 months to Jun 30, 2023
|
FY2021
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Expenses | |||||
| General and administrative | |||||
| Professional fees | |||||
| Salaries and benefits | |||||
| Patent | |||||
| Amortisation of property, plant and equipment | |||||
| Travel | |||||
| Amortisation of office leases | |||||
| Filing and transfer agent | |||||
| Advertising and investor relations | |||||
| Amortisation of intangible assets | |||||
| Project investigation | |||||
| Demonstration Plant operations | |||||
| Management and directors' fees | |||||
| Share-based compensation | |||||
| Total demonstration plant operations costs | |||||
| Consulting fees | |||||
| Separation benefits | |||||
| Other | |||||
| Foreign exchange loss (gain) | |||||
| Loss from operations | |||||
| Gain on deconsolidation of subsidiaries | |||||
| Impairment expense | |||||
| Investment loss from Smackover Lithium | |||||
| Fair value gain on financial asset - FID | |||||
| Fair value gain on Investment in Aqualung | |||||
| Interest and other income | |||||
| Interest expense | |||||
| Net (loss) income before income taxes | |||||
| Deferred income tax benefit (expense) | |||||
| Net (loss) income | |||||
| Other comprehensive loss | |||||
| Item that may be reclassified subsequently to income or loss: | |||||
| Currency translation differences of foreign operations | |||||
| Currency translation differences reclassified to net income | |||||
| Total comprehensive (loss) income | |||||
| Weighted average number of common shares outstanding - Basic | |||||
| Weighted average number of common shares outstanding - Diluted | |||||
| Basic (loss) earnings per share (in USD per share) | |||||
| Diluted (loss) earnings per share (in USD per share) | |||||
Loading...